[S-29] Symposium 29
Preparing for disease-modifying therapies in PD – From biomarkers, animal models to novel therapeutic approach

[S-29-3] Animal model for disease-modifying therapies in PD

^○Hodaka Yamakado (Kyoto University Hospital, Japan)

For the realization of disease-modifying therapies (DMT) in PD, appropriate animal models for the preclinical study and early and progression biomarkers in PD are essential. As a target of DMT much attention have been paid for mitochondria and alpha synuclein, especially. The aim of this symposium is, 1) to update recent findings in biomarkers and animal models in PD including its prodromal stage, and 2) to introduce novel therapeutic approach, focusing on mitochondria and alpha-synuclein which are the key players in idiopathic PD.

2000 Kyoto University School of Medicine
2000- Resident in Internal medicine, Toranomon Hospital
2003- Clinical Fellow, Dept. of Neurology, Kyoto University Hospital
2005- Graduate student, Kyoto University Graduate School of Medicine
2009- Assistant Professor, Dept. of Neurology, Kyoto University Hospital
2010. 9- Clinical Fellow, Dept. of Neurology, Takeda General Hospital
2011- Assistant Professor, Dept. of Neurology, Kyoto University Hospital
(2015.7-2017.1) Visiting Scholar, Dept. of Neurosciences, University of California, San Diego
2019-　　 Research associate professor, Dept. of Neurology, Kyoto University Hospital